STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk (STARFISH)
Recruitment status was Recruiting
The purpose of this study is to perform exploratory analyses to evaluate rates of functional and structural change in glaucoma, to identify predictors of rapid progression in patients with glaucoma and to identify possible genetic factors and biomarkers associated with the disease.
Primary Open Angle Glaucoma
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk (STARFISH)|
|Study Start Date:||September 2011|
|Estimated Study Completion Date:||September 2015|
|Estimated Primary Completion Date:||October 2013 (Final data collection date for primary outcome measure)|
|Primary Open Angle Glaucoma|
To identify and combine a set of predictors (i.e. by statistical modeling, machine learning classifiers or neural networks) to predict progression in glaucoma patients To determine how to most sensitively and specifically determine progression for a trial of a potential neuroprotective agent.
To evaluate genetic and other potential biomarkers associated with progression in glaucoma.
To evaluate tests currently used on glaucoma patients to better predict which ones are most sensitive to detect disease progression and measure rates of change.
To assess progression by structural and functional tests:
- Optic disc stereophotographs
- Cirrus OCT
- RTVue OCT
- Standard Automated Perimetry (SAP)
- Frequency Doubling Technology Matrix
Please refer to this study by its ClinicalTrials.gov identifier: NCT01442896
|United States, California|
|Hamilton Glaucoma Center, UCSD||Recruiting|
|La Jolla, California, United States, 92093|
|Contact: Eunice Williams-Steppe, MA 858-822-1133 email@example.com|
|Contact: Cheryl RudyGoodness, MPH 858-822-1896 firstname.lastname@example.org|
|Principal Investigator: Robert N Weinreb, MD|
|Sub-Investigator: Felipe A Medeiros, MD, PhD|